Short answer
Aquestive Therapeutics, Inc. (AQST) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M (down 5.4% year over year) with net income of −$15M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- −5.4% YoY · +28.0% QoQ
- Net income
- −$15M
- −34.2% YoY · −14.0% QoQ
- Operating margin
- -89.6%
- EPS (diluted)
- −$0.14
- −7.7% YoY · −7.7% QoQ
Source: XBRL data from the Aquestive Therapeutics, Inc. (AQST) Q3 2025 10-Q on SEC EDGAR. USD.
Aquestive Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added shutdown risk: FDA action on Anaphylm could slip past January 31, 2026 PDUFA date
- Liquidity risk: delayed approval could defer $75,000 RTW payment and postpone Q1 2026 commercialization
- Regulatory risk: 505(b)(2) pathway challenges could require additional trials, increasing approval costs and timelines
- Safety risk: adverse effects could trigger restrictive labeling, REMS, or post-approval studies
- Policy risk: post-2024-election federal policy changes could affect healthcare regulation, taxes, trade, and inflation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aquestive Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.